LaMattina: Improved Phase I survival of compounds can boost R&D

02/10/2014 | Forbes

The NIH's Accelerating Medicines Partnership could be used as a model for efforts that will increase compound survival rates in early-stage studies, John LaMattina writes. He envisions an initiative involving the same organizations discussing and learning from their experience with Phase I compound attrition, which could be used to develop best practices that all biopharmaceutical companies could benefit from, he writes.

View Full Article in:

Forbes

Published in Brief: